Skip to main
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Twist Bioscience is expected to have strong long-term growth driven by their DNA synthesis technology, expansion into multiple businesses using this platform, and growth through their Factory of the Future. They believe that the company's operational scale and ongoing innovations will drive continued revenue growth and gross margin expansion. Additionally, recent developments in AI-driven orders and expanded customer base further strengthen their positive outlook. With a strong focus on cost efficiency and potential for expanding DNA manufacturing capacity, Twist Bioscience is well positioned for continued growth and profitability. Their valuation is based on a sum-of-the-parts method and a strong buy rating is maintained given the opportunities in NGS and AI drug development.

Bears say

Twist Bioscience is highly reliant on its silicon-based DNA synthesis platform, which makes up the majority of its revenue. However, any hiccups in execution or slower progress on key milestones could negatively impact the company's long-term profitability. Additionally, while the company is seeing growth in its core NGS products and in demand from AI-enabled drug discovery, there is a risk that these end markets may not grow as quickly as expected. Overall, there are execution and market growth risks that may lead to lower-than-expected financial performance for Twist Bioscience.

TWST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 9 analysts, TWST has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.